免疫チェックポイント阻害剤は、体の免疫系と連携してがん細胞と戦う薬物の一種です。しかし、ほとんどの患者はこれらの治療法に反応しません。腫瘍に対する体の免疫反応の抑制に関与する 2 つのタンパク質を標的とする、より新しいクラスの薬剤があります。
Phase I of clinical trials has shown some exciting results, which were conducted in 19 patients suffering from 癌 with the molecule M7824. These researchers are also undertaking trials with those suffering from 膵臓癌 and those infected with HPV.
There are many other trials and experiments being taken to treat and がん治療 more effectively in different research institutes. This drug with a dual approach will be a boon in the がんの治療, as with a single molecule, multiple therapies are included.
